Posted by kinasepro on October 4, 2006
Hi TargeGen, Kinasepro cares less about who you are (and who are you, btw?) and more about whatchagot. Don’t let’m tell you you’ve just got another VEGF inhibitor, because Kinasepro likes your application. Why does Kinasepro like your application? Because you give data. While others scoff and claim all compounds <10 uM you proudly boast your yes/src/vegf/ephb4/fgf profile! Good show. Now if you could just figure out how to sell it…
While everyone’s seen the few zillion 2,4 diamopyrimidines that seem to crop up again and again (for that matter, has anyone figured out why JACS, 2006, 2182 is a JACS?) The focus here on 2,5 adds a little zest to the mix and proves there’s more then one way into H1. Seems like there’s something special about the chlorophenol. ** Kinasepro wonders aloud about the isosteric indole.
In fact the only guys I’ve seen that used the 2,5-pyrimidine motif published: BMCL, 2006, 1320 (PDB 2C6E) and that binding strategy’s gotta be different. Ummm right?
>> Update >> With a new BMCL, data in the patent, and multiple talks at the last ACS meeting all fingers point to a SRC/Yes/EphB4 fire sale! Got a spare million?